ASH 2014: Karyopharm's Selinexor headed to registrational trials
This article was originally published in Scrip
Executive Summary
Karyopharm Therapeutics is advancing its lead oral drug candidate Selinexor into registrational clinical trials based on positive early-stage data in hematological malignancies presented on 8 December at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco.